Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
Public ClinicalTrials.gov record NCT04269200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Study identification
- NCT ID
- NCT04269200
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 805 participants
Conditions and interventions
Conditions
Interventions
- olaparib Drug
- durvalumab Biological
- durvalumab placebo Drug
- olaparib placebo Drug
- Carboplatin Drug
- Paclitaxel Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 150 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2020 (Actual)
- Primary completion
- Jul 8, 2024 (Actual)
- Completion
- Apr 1, 2027 (Estimated)
- Last update posted
- Aug 7, 2026
2020 – 2027
United States locations
- U.S. sites
- 50
- U.S. states
- 29
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Concord | California | 94520-2278 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Santa Barbara | California | 93105 | — |
| Research Site | Aurora | Colorado | 80012 | — |
| Research Site | Fort Lauderdale | Florida | 33316 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Savannah | Georgia | 31404 | — |
| Research Site | Honolulu | Hawaii | 96826 | — |
| Research Site | Arlington Heights | Illinois | 60005 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Indianapolis | Indiana | 46237 | — |
| Research Site | Louisville | Kentucky | 40207 | — |
| Research Site | Baton Rouge | Louisiana | 70817 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Saint Paul | Minnesota | 55125 | — |
| Research Site | Jackson | Mississippi | 39216 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Camden | New Jersey | 08103 | — |
| Research Site | Paramus | New Jersey | 07652 | — |
| Research Site | New York | New York | 10011 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Pinehurst | North Carolina | 28374 | — |
| Research Site | Cleveland | Ohio | 44109 | — |
| Research Site | Cleveland | Ohio | 44124 | — |
| Research Site | Dayton | Ohio | 45459 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Tulsa | Oklahoma | 74134 | — |
| Research Site | Eugene | Oregon | 97401 | — |
| Research Site | Tigard | Oregon | 97223 | — |
| Research Site | Pittsburgh | Pennsylvania | 15224 | — |
| Research Site | Providence | Rhode Island | 02905 | — |
| Research Site | Sioux Falls | South Dakota | 57105 | — |
| Research Site | Chattanooga | Tennessee | 37403 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Knoxville | Tennessee | 37920 | — |
| Research Site | Bedford | Texas | 76022 | — |
| Research Site | Dallas | Texas | 75231 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | San Antonio | Texas | 78240 | — |
| Research Site | Sugar Land | Texas | 77479 | — |
| Research Site | Tyler | Texas | 75702 | — |
| Research Site | Webster | Texas | 77598 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Seattle | Washington | 98195 | — |
| Research Site | Morgantown | West Virginia | 26505 | — |
| Research Site | Madison | Wisconsin | 53792 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04269200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04269200 live on ClinicalTrials.gov.